|Mr. Michael G. Grey||Exec. Chairman||14.85k||N/A||1953|
|Mr. Samir M. Gharib CPA, CPA, M.B.A.||Pres & CFO||454.9k||N/A||1982|
|Dr. Rosh Dias||Chief Medical Officer||623.44k||N/A||1968|
|Dr. Javier Szwarcberg M.D., M.P.H.||CEO & Director||N/A||N/A||N/A|
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Spruce Biosciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 9.